Spero Therapeutics Stock Book Value Per Share
| SPRO Stock | USD 1.61 0.06 3.87% |
Spero Therapeutics fundamentals help investors to digest information that contributes to Spero Therapeutics' financial success or failures. It also enables traders to predict the movement of Spero Stock. The fundamental analysis module provides a way to measure Spero Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spero Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.03 | 1.93 | |
| Tangible Book Value Per Share | 2.03 | 1.93 |
Spero | Book Value Per Share |
Spero Therapeutics Company Book Value Per Share Analysis
Spero Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Spero Therapeutics Book Value Per Share | 2.02 X |
Most of Spero Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spero Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Spero Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Spero Therapeutics is extremely important. It helps to project a fair market value of Spero Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Spero Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spero Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spero Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Spero Book Value Per Share Historical Pattern
Today, most investors in Spero Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spero Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Spero Therapeutics book value per share as a starting point in their analysis.
Spero Therapeutics Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Spero Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Spero Therapeutics is about 2.017 times. This is 218.65% lower than that of the Biotechnology sector and 100.81% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.9% higher than that of the company.
Spero Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spero Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spero Therapeutics could also be used in its relative valuation, which is a method of valuing Spero Therapeutics by comparing valuation metrics of similar companies.Spero Therapeutics is currently under evaluation in book value per share category among related companies.
Spero Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spero Therapeutics from analyzing Spero Therapeutics' financial statements. These drivers represent accounts that assess Spero Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spero Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 174.7M | 434.1M | 494.6M | 65.0M | 77.5M | 135.7M | |
| Enterprise Value | 150.5M | 356.7M | 389.4M | (37.4M) | 6.7M | 6.3M |
Spero Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.69 % | ||||
| Current Valuation | 12.44 M | ||||
| Shares Outstanding | 53.89 M | ||||
| Shares Owned By Insiders | 20.16 % | ||||
| Shares Owned By Institutions | 26.19 % | ||||
| Number Of Shares Shorted | 513.16 K | ||||
| Price To Earning | 81.20 X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 0.85 X | ||||
| Revenue | 96.73 M | ||||
| Gross Profit | (42.11 M) | ||||
| EBITDA | 20.11 M | ||||
| Net Income | 22.81 M | ||||
| Cash And Equivalents | 45.4 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 5.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.65 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (32.99 M) | ||||
| Short Ratio | 1.62 X | ||||
| Earnings Per Share | 0.43 X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 46 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 86.77 M | ||||
| Total Asset | 182.39 M | ||||
| Retained Earnings | (391.07 M) | ||||
| Working Capital | 94.06 M | ||||
| Current Asset | 7.3 M | ||||
| Current Liabilities | 6.04 M | ||||
| Net Asset | 182.39 M |
About Spero Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spero Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spero Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spero Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:Check out Spero Therapeutics Piotroski F Score and Spero Therapeutics Altman Z Score analysis. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Spero Stock analysis
When running Spero Therapeutics' price analysis, check to measure Spero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spero Therapeutics is operating at the current time. Most of Spero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spero Therapeutics' price. Additionally, you may evaluate how the addition of Spero Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Spero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.43 | Revenue Per Share 1.969 | Quarterly Revenue Growth 0.55 | Return On Assets 0.109 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.